- Stocks
- Pharma & Healthcare
- Gufic Biosciences
Gufic Biosciences share price
NSE: GUFICBIOPharma & HealthcareDrug Manufacturers - Specialty & Generic
Gufic Biosciences at a glance
Gufic Biosciences (NSE: GUFICBIO) closed at ₹404.00 on 19 Oct 2026, up 0.50% on the day. With a market capitalisation of ₹4,051 Cr, it ranks 875th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 63.1× trailing earnings, against a return on equity of 11.6% in FY25. Over the past year the share price has risen 10.7%. Its 52-week range is ₹268.00 (9 Mar 2026) to ₹467.80 (7 Sep 2026); the last close is 13.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹252 Cr (+22.8% year on year) and net profit ₹22 Cr (+183.7%), on a consolidated basis. Promoters held 72.50% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹4,051 CrRank 875 on NSE
- P/E (trailing)
- 63.1×
- Price to book
- 5.61×FY25
- EPS (TTM)
- ₹6.40to Q4 FY26
- ROE
- 11.6%FY25
- ROCE
- 15.2%FY25
- Debt to equity
- 0.52FY25
- Net profit margin
- 8.5%FY25
- Book value / share
- ₹59.94FY25
- Dividend payout
- 1.4%FY25
- 52-week high
- ₹467.807 Sep 2026
- 52-week low
- ₹268.009 Mar 2026
- 1-year return
- +10.7%
- RSI (14-day)
- 41.9
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.50% | −3.2% | −4.9% | +3.0% | +10.7% |
Gufic Biosciences quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹203 Cr | ₹204 Cr | ₹208 Cr | ₹205 Cr | ₹224 Cr | ₹237 Cr | ₹231 Cr | ₹252 Cr |
| Revenue YoY | +4.0% | −5.0% | +3.0% | +5.1% | +10.3% | +16.1% | +11.4% | +22.8% |
| Net profit | ₹21 Cr | ₹22 Cr | ₹19 Cr | ₹8 Cr | ₹13 Cr | ₹17 Cr | ₹12 Cr | ₹22 Cr |
| Net profit YoY | +1.2% | −6.2% | −13.3% | −61.5% | −37.3% | −22.7% | −35.7% | +183.7% |
| Net margin | 10.3% | 10.7% | 9.3% | 3.8% | 5.8% | 7.1% | 5.4% | 8.7% |
| EPS | ₹2.08 | ₹2.17 | ₹1.93 | ₹0.77 | ₹1.30 | ₹1.68 | ₹1.24 | ₹2.18 |
Gufic Biosciences financials
| Item | FY24 | FY25 |
|---|---|---|
| Revenue | ₹807 Cr | ₹820 Cr |
| Operating profit | ₹116 Cr | ₹94 Cr |
| Net profit | ₹86 Cr | ₹70 Cr |
| EPS (₹) | ₹9.00 | ₹7.00 |
| Cash from operations | −₹7 Cr | ₹123 Cr |
| Total debt | ₹154 Cr | ₹131 Cr |
| Shareholders' equity | ₹533 Cr | ₹601 Cr |
Gufic Biosciences shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.51% | 72.51% | 72.50% | 72.50% | 72.50% | 72.50% |
| Foreign institutions | 0.31% | 0.32% | 0.34% | 0.44% | 0.42% | 0.46% |
| Domestic institutions | 3.39% | 3.38% | 3.65% | 3.74% | 3.83% | 3.68% |
| Non-institutions | 23.79% | 23.80% | 23.51% | 23.32% | 23.24% | 23.36% |
Gufic Biosciences vs peers
The listed Pharma & Healthcare companies nearest to Gufic Biosciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| JSLLJeena Sikho Lifecare | ₹367.20 | −5.77% | −51.9% | ₹4,564 Cr | 20.7 | — |
| ORCHPHARMAOrchid Pharma | ₹891.00 | −1.98% | +19.3% | ₹4,519 Cr | 217.8 | — |
| GUFICBIOGufic Biosciences | ₹404.00 | +0.50% | +10.7% | ₹4,051 Cr | 63.1 | — |
| SMSPHARMASMS Pharmaceuticals | ₹432.55 | −3.90% | +57.6% | ₹4,051 Cr | 38.8 | — |
| GUJTHEMGujarat Themis Biosyn | ₹358.50 | −3.63% | −14.7% | ₹3,906 Cr | 83.8 | — |
| AARTIDRUGSAarti Drugs | ₹399.00 | +0.76% | −22.4% | ₹3,642 Cr | 18.7 | — |
| UNICHEMLABUnichem Laboratories | ₹504.00 | −1.40% | +4.8% | ₹3,548 Cr | 14.1 | — |
Ask anything about Gufic Biosciences
Pivot answers on the live chart with evidence you can check, and tests strategies against GUFICBIO's own history. Try: “Why has GUFICBIO moved over the last three months?” · “Backtest a 50-day moving-average crossover on GUFICBIO over five years” · “Compare GUFICBIO with JSLL on margins and valuation”
Frequently asked questions about Gufic Biosciences
What is the share price of Gufic Biosciences today?
Gufic Biosciences (NSE: GUFICBIO) last closed at ₹404.00 on 19 Oct 2026. Its 52-week high is ₹467.80 and its 52-week low is ₹268.00.
What is the market cap of Gufic Biosciences?
Gufic Biosciences' market capitalisation is ₹4,051 Cr (₹4,051 Cr) at the 19 Oct 2026 close, ranking 875th among the NSE companies Pivot tracks.
What is the P/E ratio of Gufic Biosciences?
Gufic Biosciences trades at a trailing P/E of 63.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 38.8.
What is the ROE and ROCE of Gufic Biosciences?
Return on equity was 11.6% in FY25 and return on capital employed was 15.2% in FY25 (consolidated figures).
Is Gufic Biosciences a debt-free company?
No. Gufic Biosciences' debt-to-equity ratio was 0.52 in FY25, with total debt of ₹131 Cr.
What were Gufic Biosciences' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Gufic Biosciences reported revenue of ₹252 Cr, +22.8% year on year, and net profit of ₹22 Cr, +183.7% year on year.
How has Gufic Biosciences stock performed over the last year?
Gufic Biosciences' share price has risen 10.7% over the past year, +3.0% over three months and −4.9% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Gufic Biosciences?
As of 30 Jun 2026: promoters 72.50%, foreign institutions 0.46%, domestic institutions 3.68%, non-institutions 23.36%.
Who are Gufic Biosciences' competitors?
The listed Pharma & Healthcare companies closest to Gufic Biosciences by market cap are Jeena Sikho Lifecare, Orchid Pharma, SMS Pharmaceuticals, Gujarat Themis Biosyn, Aarti Drugs and Unichem Laboratories.
Is Gufic Biosciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Gufic Biosciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GUFICBIO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text